الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 128 |  |  |
| | | from | 128 | | |
Abstract
HCC is the most deleterious consequences of cirrhosis. HCC develops at a rate of 3–5% each year in HCV cirrhosis people.
AFP was utilized as HCC marker, despite the limited sensitivity and positive predictive value. As a result, novel biomarkers are required for early HCC diagnosis.
CXCL9 is a tiny cytokine of the CXC chemokine class that causes tissue extravasation by inducing chemotaxis and promoting leukocyte growth and division.
CXCL9 was noted to be highly expressed in multiple malignancies including HCC tissue.
Pentraxin3 a component of the pentraxin superfamily, is involved in innate immunity and inflammation by activating and regulating the complement system, interacting with microbial moieties of certain microorganisms and the regulation of tissue remodeling and repair.
Increased pentraxin3 expressions have been involved in various cancers. Nevertheless, not much is known about pentraxin3’s role in HCC related to chronic HCV.